恶性胸膜间皮瘤患者穿刺道预防性照射:一项开放标签、多中心、III期随机试验
这项开放标签、多中心、III期随机试验纳入375例恶性胸膜间皮瘤患者,比较胸壁操作后预防性放疗(186例)与不放疗(189例)对6个月内胸壁转移发生率的影响。结果显示两组胸壁转移发生率无显著差异(3.2% vs 5.3%,OR 0.60,95%CI 0.17-1.86,P=0.44)。作者结论认为不推荐常规对胸壁操作部位进行预防性照射。
要点
- 胸壁操作后预防性放疗组与不放疗组6个月胸壁转移发生率无显著差异(3.2% vs 5.3%)。
- 预防性放疗组最常见不良事件为放射性皮炎,1级51.6%、2级10.2%、3级0.5%。
- 作者结论认为恶性胸膜间皮瘤患者胸壁操作部位无常规预防性照射的适应证。
核心结论
- 作者结论认为,对恶性胸膜间皮瘤患者的胸壁操作部位常规使用预防性照射没有作用。
研究设计与样本
- 开放标签、多中心、III期随机试验,2012年7月30日至2015年12月12日从54个中心招募375例恶性胸膜间皮瘤患者,随机分配至预防性放疗组(n=186)或不放疗组(n=189)。
- 患者在接受胸壁操作后随机分组,预防性放疗在操作后42天内进行;排除开放胸廓切开术、针吸活检和留置胸膜导管。
- 预防性放疗剂量为21 Gy分3次,连续3个工作日内完成,使用单一电子野并调整以最大化覆盖从皮肤表面到胸膜的穿刺道。
- 主要终点为随机分组后6个月内胸壁转移的发生率,在意向治疗人群中评估;分层因素包括上皮样组织学和是否计划给予化疗。
主要发现
- 预防性放疗组与不放疗组6个月内胸壁转移发生率无显著差异(例数[%]:6[3.2] vs 10[5.3];比值比0.60;95%CI 0.17至1.86;P=0.44)。
- 预防性放疗组最常见的放疗相关不良事件为皮肤毒性:1级放射性皮炎96例(51.6%),2级19例(10.2%),3级1例(0.5%)(不良事件通用术语标准4.0版)。
关键数值与推荐
- 预防性放疗剂量为21 Gy分3次,连续3个工作日内完成,使用单一电子野覆盖从皮肤表面到胸膜的穿刺道。
- 主要终点6个月胸壁转移发生率:预防性放疗组6例(3.2%)vs 不放疗组10例(5.3%),OR 0.60(95%CI 0.17-1.86),P=0.44。
临床怎么用
- 作者结论认为,恶性胸膜间皮瘤患者胸壁操作部位无常规预防性照射的适应证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain. In this study, we aimed to determine the efficacy of prophylactic radiotherapy in reducing the incidence of chest wall metastases (CWM) after a procedure in MPM. METHODS: After undergoing a chest wall procedure, patients with MPM were randomly assigned to receive prophylactic radiotherapy (within 42 days of the procedure) or no radiotherapy. Open thoracotomies, needle biopsies, and indwelling pleural catheters were excluded. Prophylactic radiotherapy was delivered at a dose of 21 Gy in three fractions over three consecutive working days, using a single electron field adapted to maximize coverage of the tract from skin surface to pleura. The primary outcome was the incidence of CWM within 6 months from random assignment, assessed in the intention-to-treat population. Stratification factors included epithelioid histology and intention to give chemotherapy. RESULTS: Between July 30, 2012, and December 12, 2015, 375 patients were recruited from 54 centers and randomly assigned to receive prophylactic radiotherapy (n = 186) or no prophylactic radiotherapy (n = 189). Participants were well matched at baseline. No significant difference was seen in the incidence of CWM at 6 months between the prophylactic radiotherapy and no radiotherapy groups (no. [%]: 6 [3.2] v 10 [5.3], respectively; odds ratio, 0.60; 95% CI, 0.17 to 1.86; P = .44). Skin toxicity was the most common radiotherapy-related adverse event in the prophylactic radiotherapy group, with 96 patients (51.6%) receiving grade 1; 19 (10.2%), grade 2; and 1 (0.5%) grade 3 radiation dermatitis (Common Terminology Criteria for Adverse Events, version 4.0). CONCLUSION: There is no role for the routine use of prophylactic irradiation to chest wall procedure sites in patients with MPM.
引用
- Bayman N, Appel W, Ashcroft L, et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. J Clin Oncol. 2019. PMID: 30920878. doi:10.1200/JCO.18.01678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。